Want to see BTAIQ full AI Analyst Report?
Total Valuation
Bioxcel Therapeutics has a market cap or net worth of $2.31M. The enterprise value is $133.37.
Market Cap$2.31M
Enterprise Value$133.37
Share Statistics
Bioxcel Therapeutics has 31,305,498 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding31,305,498
Owned by Insiders2.75%
Owned by Institutions5.49%
Financial Efficiency
Bioxcel Therapeutics’s return on equity (ROE) is ― and return on invested capital (ROIC) is ―.
Return on Equity (ROE)―
Return on Assets (ROA)―
Return on Invested Capital (ROIC)―
Return on Capital Employed (ROCE)―
Revenue Per Employee―
Profits Per Employee―
Employee Count29
Asset Turnover―
Inventory Turnover―
Valuation Ratios
The current PE Ratio of Bioxcel Therapeutics is ―. Bioxcel Therapeutics’s PEG ratio is 0.00369.
PE Ratio―
PS Ratio30.42
PB Ratio-0.20
Price to Fair Value―
Price to FCF-0.34
Price to Operating Cash Flow―
PEG Ratio0.00369
Income Statement
In the last 12 months, Bioxcel Therapeutics had revenue of ― and earned ― in profits. Earnings per share was ―.
Revenue―
Gross Profit―
Operating Income―
Pretax Income―
Net Income―
EBITDA―
Earnings Per Share (EPS)―
Cash Flow
In the last 12 months, operating cash flow was ― and capital expenditures ―, giving a free cash flow of ― billion.
Operating Cash Flow―
Free Cash Flow―
Free Cash Flow per Share―
Dividends & Yields
Bioxcel Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta2.43
52-Week Price Change-98.83%
50-Day Moving Average0.81
200-Day Moving Average1.33
Relative Strength Index (RSI)19.49
Average Volume (3m)11.67M
Important Dates
Bioxcel Therapeutics upcoming earnings date is ―, ―.
Last Earnings Date―
Next Earnings Date―
Ex-Dividend Date―
Financial Position
Bioxcel Therapeutics as a current ratio of ―, with Debt / Equity ratio of ―
Current Ratio―
Quick Ratio―
Debt to Market Cap―
Net Debt to EBITDA―
Interest Coverage Ratio―
Taxes
In the past 12 months, Bioxcel Therapeutics has paid ― in taxes.
Income Tax―
Effective Tax Rate―
Enterprise Valuation
Bioxcel Therapeutics EV to EBITDA ratio is ―, with an EV/FCF ratio of ―.
EV to Sales―
EV to EBITDA―
EV to Free Cash Flow―
EV to Operating Cash Flow―
Balance Sheet
Bioxcel Therapeutics has ― in cash and marketable securities with $104.45M in debt, giving a net cash position of ― billion.
Cash & Marketable Securities―
Total Debt$104.45M
Net Cash―
Net Cash Per Share―
Tangible Book Value Per Share―
Margins
Gross margin is ―, with operating margin of ―, and net profit margin of ―.
Gross Margin―
Operating Margin―
Pretax Margin―
Net Profit Margin―
EBITDA Margin―
EBIT Margin―
Analyst Forecast
The average price target for Bioxcel Therapeutics is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target―
Price Target Upside―
Analyst Consensus―
Analyst Count0
Revenue Growth Forecast-14.52%
EPS Growth Forecast66.63%